WO2008011483A3 - Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds - Google Patents

Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds Download PDF

Info

Publication number
WO2008011483A3
WO2008011483A3 PCT/US2007/073813 US2007073813W WO2008011483A3 WO 2008011483 A3 WO2008011483 A3 WO 2008011483A3 US 2007073813 W US2007073813 W US 2007073813W WO 2008011483 A3 WO2008011483 A3 WO 2008011483A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
chronic pain
diamino
hetero
aryl
Prior art date
Application number
PCT/US2007/073813
Other languages
French (fr)
Other versions
WO2008011483A2 (en
Inventor
John E Donello
Fabien J Schweighoffer
Bertrand Leblond
Original Assignee
Allergan Inc
John E Donello
Fabien J Schweighoffer
Bertrand Leblond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, John E Donello, Fabien J Schweighoffer, Bertrand Leblond filed Critical Allergan Inc
Publication of WO2008011483A2 publication Critical patent/WO2008011483A2/en
Publication of WO2008011483A3 publication Critical patent/WO2008011483A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed herein are methods of treating a patient suffering from one or more types of chronic pain using compounds of the following formula (II) wherein the variables have the meaning defined in the specification.
PCT/US2007/073813 2006-07-19 2007-07-18 Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds WO2008011483A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80779906P 2006-07-19 2006-07-19
US60/807,799 2006-07-19

Publications (2)

Publication Number Publication Date
WO2008011483A2 WO2008011483A2 (en) 2008-01-24
WO2008011483A3 true WO2008011483A3 (en) 2009-04-16

Family

ID=38957598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073813 WO2008011483A2 (en) 2006-07-19 2007-07-18 Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds

Country Status (1)

Country Link
WO (1) WO2008011483A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109287A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008109286A1 (en) * 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
EP2131837B1 (en) 2007-03-06 2012-05-16 Allergan, Inc. Specific 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide derivative for use in the treatment of certain cognitive disorders
US8173683B2 (en) 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
ES2664749T3 (en) * 2013-08-15 2018-04-23 Allergan, Inc. Salt (l) - (+) - (-) - (2R, 3S) -2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one tartrate , its method of production and use
EP3046920B1 (en) 2013-09-20 2021-08-04 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
HUE040220T2 (en) 2013-10-29 2019-02-28 Biomarin Pharm Inc N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
US10227312B2 (en) 2015-03-11 2019-03-12 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720852A1 (en) * 1993-08-13 1996-07-10 Seikagaku Corporation Remedy for nervous diseases
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
WO2006081276A1 (en) * 2005-01-26 2006-08-03 Allergan, Inc. 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
WO2008011487A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0720852A1 (en) * 1993-08-13 1996-07-10 Seikagaku Corporation Remedy for nervous diseases
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
WO2006081276A1 (en) * 2005-01-26 2006-08-03 Allergan, Inc. 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
WO2006081252A2 (en) * 2005-01-26 2006-08-03 Allergan, Inc. Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics
WO2008011487A2 (en) * 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANIMAL CELL TECHNOLOGY: BASIC & APPLIED ASPECTS, PROCEEDINGS OF THE ANNUAL MEETING OF THE JAPANESE ASSOCIATION FOR ANIMAL CELL TECHNOLOGY, 10TH, NAGOYA, NOV. 5-8, 1997 , MEETING DATE 1997, 33-36. EDITOR(S): KITAGAWA, YASUO; MATSUDA, T.; IIJIMA, SHIN, 1999 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; INOKUCHI, JIN-ICHI: "Induction of ganglioside biosynthesis, neurite outgrowth and functional synapse formation by a synthetic ceramide analog", XP002506252, retrieved from STN Database accession no. 1999:276552 *

Also Published As

Publication number Publication date
WO2008011483A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
WO2008011483A3 (en) Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
WO2008011478A3 (en) Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008011487A3 (en) L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
WO2006110816A3 (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2006042100A3 (en) Method for the treatment of polycystic kidney disease
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
UA96126C2 (en) Compound for inhibition of rhokinase activity, pharmaceutical composition comprising such a compound and method of inhibiting the activity of a rhokinase
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
WO2005117870A3 (en) Combination of proton pump inhibitor, buffering agent, and prokinetic agent
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007014278A3 (en) B-cell reduction using cd37-specific and cd20-specific binding molecules
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
WO2008157740A3 (en) Faah inhibitors
WO2008073452A8 (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2007089715A3 (en) Method for treatment of neuropathic pain
WO2010071783A8 (en) Thiazoles as cannabinoid receptor ligands
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
AP2246A (en) Pesticidal composition and method for seed treatment.
AU2016204334A1 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008013660A3 (en) Inhibitors of advanced glycation end products
WO2007022102A3 (en) Pentacyclic kinase inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07813075

Country of ref document: EP

Kind code of ref document: A2